Atty's Docket:101195-38

Proposed Amendm nt to Claims

1. – 14. (Canceled)

15. (New) A method for improving the stable transfer of genetic material into a mammalian cell, the method comprising the steps, of

(a) preparing a transfected mammalian cell by transferring into said cell,

(i) a first polynucleotide comprising a promotor operably linked to the coding sequence of p21; and

(ii) a second polynucleotide comprising a promotor operably linked to a coding sequence;

(b) maintaining said transfected mammalian cell under conditions conducive to synthesizing p21.

16. (New) The method of claim 15, wherein the first and/or second polynucleotide comprises a viral vector.

17. (New) The method of claim 16, wherein the viral vector is selected from the group consisting of retroviral vectors, adenoviral vectors, baculoviral vectors, parvoviral vectors and herpes viral vectors.

18. (New) The method of claim 15, wherein the viral vector is an adenoviral vector.

19. (New) The method of claim 15, wherein the mammalian cell is transfected *in vitro*.

20. (New) The method of claim 15, wherein the mammalian cell is an established cell line or a primary culture.

21. (New) The method of claim 15 wherein the mammalian cell is transfected *in vivo*.

22. (New) The m thod of claim 21 wherein the mammalian cell is a rodent cell.

23. (New) The method of claim 21 wherein the mammalian cell is a human cell.

24. (New) The method of claim 15, wherein the mammalian cell is tumorigenic or non-tumorigenic.

25. (New) The method of claim 15, wherein the improved stability results from p21-mediated inhibition of apoptosis.

C' cont'd

26. (New) The method of claim 15 wherein the improved stability results from the p21-mediated inhibition of cytoxicity.